TNFRSF12A antibody (PE)
-
- Target See all TNFRSF12A Antibodies
- TNFRSF12A (Tumor Necrosis Factor Receptor Superfamily, Member 12A (TNFRSF12A))
-
Reactivity
- Human, Mouse
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This TNFRSF12A antibody is conjugated to PE
-
Application
- Flow Cytometry (FACS)
- Specificity
- The mouse monoclonal antibody ITEM-4 recognizes an extracellular epitope of CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis.
- Cross-Reactivity (Details)
- Human, Mouse
- Purification
- Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
- Immunogen
- human CD266-transfected P815 cells
- Clone
- ITEM-4
- Isotype
- IgG2b
- Top Product
- Discover our top product TNFRSF12A Primary Antibody
-
-
- Application Notes
- Flow cytometry: Recommended dilution: 2-4 μg/mL.
- Comment
-
The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
- Restrictions
- For Research Use only
-
- Concentration
- 0.1 mg/mL
- Buffer
- Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C
- Storage Comment
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer." in: Experimental and therapeutic medicine, Vol. 2, Issue 1, pp. 103-108, (2012) (PubMed).
: "Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 185, Issue 3, pp. 1593-605, (2010) (PubMed).
: "Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 170, Issue 1, pp. 341-8, (2002) (PubMed).
: "
-
Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer." in: Experimental and therapeutic medicine, Vol. 2, Issue 1, pp. 103-108, (2012) (PubMed).
-
- Target
- TNFRSF12A (Tumor Necrosis Factor Receptor Superfamily, Member 12A (TNFRSF12A))
- Alternative Name
- CD266 / TWEAK R (TNFRSF12A Products)
- Synonyms
- CD266 antibody, FN14 antibody, TWEAKR antibody, AI255180 antibody, C87282 antibody, Fn14 antibody, HPIP antibody, TWEAK-R antibody, TweakR antibody, TNF receptor superfamily member 12A antibody, tumor necrosis factor receptor superfamily, member 12a antibody, TNFRSF12A antibody, Tnfrsf12a antibody
- Background
- TNF receptor superfamily member 12A,CD266 / TWEAK R (TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14) is a receptor for CD255 / TWEAK, the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.,TWEAKR, FN14, TNFRSF12A
- Gene ID
- 51330
- UniProt
- Q9NP84
- Pathways
- Apoptosis, Regulation of Cell Size
-